Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
- Conditions
- Interventions
- Drug: Target GeneDrug: Olaparib tabletDrug: Temozolomide capsuleDrug: AnlotinibDrug: Trametinib tabletDrug: DabrafenibDrug: Vebreltinib Enteric CapsulesDrug: Alpelisib PillDrug: Sacituzumab Govitecan-Hziy 180 MGDrug: Lenvatinib CapsulesDrug: Pazopanib PillDrug: Palbociclib PillDrug: ChidamideDrug: PD-1/PD-L1/PD-1&CTLA4 inhibitor
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06739395
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Target Recruit Count
- 45
- Registration Number
- NCT06699498
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.
- Conditions
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 448
- Registration Number
- NCT06699576
Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 40
- Registration Number
- NCT06678230
- Locations
- 🇨🇳
Cancer Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin Province, China, Changchun, Jilin, China
Tirellizumab+Anlotinib VS Anlotinib for MSS-type CRC
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- fan li
- Target Recruit Count
- 115
- Registration Number
- NCT06573424
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, China
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06506838
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳Guangdong provincial people's hospital, Guangzhou, Guangdong, China
Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 27
- Registration Number
- NCT06483672
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 75
- Registration Number
- NCT06482086
- Locations
- 🇨🇳
West China hospital, Chengdu, Sichuan, China
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-06-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06456138
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
- Conditions
- Interventions
- First Posted Date
- 2024-05-02
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06396585
- Locations
- 🇨🇳
Fujian cancer hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.